Award details

Contained trial of modified capripox-rinderpest vaccine in Kenya

ReferenceBBS/E/I/00000619
Principal Investigator / Supervisor Professor Thomas Barrett
Co-Investigators /
Co-Supervisors
Institution The Pirbright Institute
DepartmentThe Pirbright Institute Department
Funding typeResearch
Value (£) 19,401
StatusCompleted
TypeInstitute Project
Start date 01/04/1997
End date 31/03/1999
Duration24 months

Abstract

A bi-valent recombinant vaccine, for use in cattle and small ruminants against rinderpest/peste des petits ruminants and lumpy skin disease/sheep and goat pox, is based on the expression of the H and F genes of rinderpest virus in a sheep pox virus vector. Initial trials in containment at Pirbright indicated that the recombinant vaccine is effective in protecting UK sourced animals over intervals of a month or so. This project aims to assess the long term (up to 3 years) efficacy and safety of the vaccine in African animals.

Summary

unavailable
Committee Closed Committee - Animal Sciences (AS)
Research TopicsX – not assigned to a current Research Topic
Research PriorityX – Research Priority information not available
Research Initiative X - not in an Initiative
Funding SchemeX – not Funded via a specific Funding Scheme
terms and conditions of use (opens in new window)
export PDF file